These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 26481591

  • 1. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study.
    Giustino G, Baber U, Mastoris I, Vlachojannis GJ, Yu J, Teirstein PS, Downey WE, Batchelor WB, Casterella PJ, Nikolsky E, Wong SC, Theodoropoulos KN, Dangas GD, Mehran R.
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):703-9. PubMed ID: 26481591
    [Abstract] [Full Text] [Related]

  • 2. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R, Nikolsky E, Kirtane AJ, Caixeta A, Wong SC, Teirstein PS, Downey WE, Batchelor WB, Casterella PJ, Kim YH, Fahy M, Dangas GD.
    JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
    [Abstract] [Full Text] [Related]

  • 3. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B, Cheng WJ, Li YF, Cao Z, Yang Q, Zhao YX, Guo YH, Zhou YJ.
    Catheter Cardiovasc Interv; 2008 Dec 01; 72(7):958-65. PubMed ID: 19021282
    [Abstract] [Full Text] [Related]

  • 4. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators.
    Bertrand ME, Esplugas E, Piessens J, Rasch W.
    Circulation; 2000 Jan 18; 101(2):131-6. PubMed ID: 10637198
    [Abstract] [Full Text] [Related]

  • 5. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, Chung WY, Joo GW, Chae IH, Choi DJ, Oh BH, Lee MM, Park YB, Kim HS.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):924-30. PubMed ID: 16949481
    [Abstract] [Full Text] [Related]

  • 6. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
    Bolognese L, Falsini G, Schwenke C, Grotti S, Limbruno U, Liistro F, Carrera A, Angioli P, Picchi A, Ducci K, Pierli C.
    Am J Cardiol; 2012 Jan 01; 109(1):67-74. PubMed ID: 21943940
    [Abstract] [Full Text] [Related]

  • 7. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.
    Liss P, Persson PB, Hansell P, Lagerqvist B.
    Kidney Int; 2006 Nov 01; 70(10):1811-7. PubMed ID: 17003814
    [Abstract] [Full Text] [Related]

  • 8. Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.
    Le Feuvre C, Batisse A, Collet JP, Batisse JP, Choussat R, Beygui F, Helft G, Montalescot G, Metzger JP.
    Catheter Cardiovasc Interv; 2006 Jun 01; 67(6):852-8. PubMed ID: 16649230
    [Abstract] [Full Text] [Related]

  • 9. A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention.
    Sutton AG, Ashton VJ, Campbell PG, Price DJ, Hall JA, de Belder MA.
    Catheter Cardiovasc Interv; 2002 Nov 01; 57(3):346-52. PubMed ID: 12410513
    [Abstract] [Full Text] [Related]

  • 10. Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PEPCIT study.
    Bellemain-Appaix A, Beygui F, Lesty C, Gupta S, Silvain J, Le Feuvre C, Cayla G, Allali Y, Montalescot G, Collet JP.
    Catheter Cardiovasc Interv; 2012 Apr 01; 79(5):823-33. PubMed ID: 21618678
    [Abstract] [Full Text] [Related]

  • 11. [Comparison of iodixanol (Visipaque) and ioxaglate (Hexabrix) in coronary angiography and ventriculography: a double-blind randomized study].
    Roriz R, de Gevigney G, Finet G, Nantois-Collet C, Borch KW, Amiel M, Beaune J.
    J Radiol; 1999 Jul 01; 80(7):727-32. PubMed ID: 10431273
    [Abstract] [Full Text] [Related]

  • 12. The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study.
    Bolognese L, Falsini G, Grotti S, Limbruno U, Liistro F, Carrera A, Angioli P, Picchi A, Ducci K, Pierli C.
    J Cardiovasc Med (Hagerstown); 2010 Mar 01; 11(3):199-206. PubMed ID: 19829124
    [Abstract] [Full Text] [Related]

  • 13. A randomized trial comparing the impact of a nonionic (Iomeprol) versus an ionic (Ioxaglate) low osmolar contrast medium on abrupt vessel closure and ischemic complications after coronary angioplasty.
    Schräder R, Esch I, Ensslen R, Fach WA, Merle H, Scherer D, Sievert H, Spies HF, Zeplin HE.
    J Am Coll Cardiol; 1999 Feb 01; 33(2):395-402. PubMed ID: 9973019
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial.
    Davidson CJ, Laskey WK, Hermiller JB, Harrison JK, Matthai W, Vlietstra RE, Brinker JA, Kereiakes DJ, Muhlestein JB, Lansky A, Popma JJ, Buchbinder M, Hirshfeld JW.
    Circulation; 2000 May 09; 101(18):2172-7. PubMed ID: 10801758
    [Abstract] [Full Text] [Related]

  • 15. Adverse reactions of low osmolar non-ionic and ionic contrast media when used together or separately during percutaneous coronary intervention.
    Juergens CP, Khaing AM, McIntyre GJ, Leung DY, Lo ST, Fernandes C, Hopkins AP.
    Heart Lung Circ; 2005 Sep 09; 14(3):172-7. PubMed ID: 16352273
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty.
    Song T, Song M, Ge Z, Li Y, Shi P, Sun M.
    J Interv Cardiol; 2017 Jun 09; 30(3):281-285. PubMed ID: 28421628
    [Abstract] [Full Text] [Related]

  • 17. The assessment of thrombotic markers utilizing ionic versus non-ionic contrast during coronary angiography and intervention trial.
    Shah B, Berger JS, Allen N, Guo Y, Sedlis SP, Xu J, Perez A, Attubato M, Slater J, Feit F.
    Catheter Cardiovasc Interv; 2016 Nov 09; 88(5):727-737. PubMed ID: 26773574
    [Abstract] [Full Text] [Related]

  • 18. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
    Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS.
    JACC Cardiovasc Interv; 2009 Jul 09; 2(7):645-54. PubMed ID: 19628188
    [Abstract] [Full Text] [Related]

  • 19. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial.
    Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF, VALOR Trial Investigators.
    Am Heart J; 2008 Oct 09; 156(4):776-82. PubMed ID: 18946896
    [Abstract] [Full Text] [Related]

  • 20. Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
    Chen Y, Hu S, Liu Y, Zhao R, Wang L, Fu G, He Q, Su X, Zheng Y, Qi X, Liu H, Wang J, Gao W, Wang M, Liu S, Zheng X, He B, Yang P, Zhou S, Gao C, Qiu C.
    EuroIntervention; 2012 Nov 22; 8(7):830-8. PubMed ID: 23045301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.